1Suppliers
2Customers
1Debt Items
20Related Chains

Bausch + Lomb Corporation Suppliers

TickerNameConfidenceEvidence
WHITECAP-BIOSCIENCES WHITECAP-BIOSCIENCES 85% On January 3, 2025, the Company, through its affiliate, acquired Whitecap Biosciences, LLC, (Whitecap Biosciences) for an upfront payment of approximately $ 28 million

Bausch + Lomb Corporation Customers

TickerNameConfidenceEvidence
PAYORS PAYORS 90% We also concentrate on managing our relationships with our payors and wholesalers
NOVALIQ-GMBH NOVALIQ-GMBH 85% utable to the increase in our operating results, as previously discussed. Investing Activities Net cash used in investing activities was $130 million and $116 million for the three months ended March…

Bausch + Lomb Corporation Debt Obligations

InstrumentDescriptionConfidenceEvidence
BLCO-DEBT Debt stack $5.1B 90% Market cache reports total debt of $5.1B.

Bausch + Lomb Corporation Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Bausch + Lomb Corporation.

Bausch + Lomb Corporation Ownership

HolderNameConfidenceEvidence
BLCO-OWNER-OAKTREE-CAPITAL-MANAGEMENT-LP OAKTREE CAPITAL MANAGEMENT LP 90% 13F overlay lists OAKTREE CAPITAL MANAGEMENT LP as top holder; 96 tracked holders.

Bausch + Lomb Corporation Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
ADGM Adagio Medical Holdings, Inc. 100.00 2
ATON AlphaTON Capital Corp 100.00 2
CLGN CollPlant Biotechnologies Ltd. 100.00 2
TRIB Trinity Biotech plc 100.00 2
ABBV AbbVie Inc. 100.00 2
AURA Aura Biosciences, Inc. 100.00 2
BLLN BillionToOne, Inc. 100.00 2
ATRA Atara Biotherapeutics, Inc. 100.00 2
BCAX Bicara Therapeutics Inc. 100.00 2
BNR Burning Rock Biotech Limited 100.00 2
BNRG Brenmiller Energy Ltd 100.00 2
ANIK Anika Therapeutics, Inc. 100.00 2
CSTE Caesarstone Ltd. 100.00 2
ACIU AC Immune SA 100.00 2
SNNUF Smith & Nephew plc 100.00 2
AORT Artivion, Inc. 100.00 2
ALC Alcon Inc. 100.00 2
AVBP ArriVent BioPharma, Inc. 100.00 2
CYTOF Altamira Therapeutics Ltd. 100.00 2
FDMT 4D Molecular Therapeutics, Inc. 100.00 2